PF-04634817 |
Katalog-Nr.GC36880 |
PF-0463481 ist ein potenter und oral aktiver dualer CCR2/CCR5-Antagonist mit vergleichbarer CCR2-Potenz bei Mensch und Nagetier (IC50 = 20,8 nM bei Ratten) und einer 10- bis 20-fach geringeren CCR5-Potenz bei Nagetieren (IC50 bei Ratte = 470 nM).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1228111-63-4
Sample solution is provided at 25 µL, 10mM.
PF-0463481, an oral CCR2/5 dual antagonist, with a favorable ocular safety profile versus intravitreal therapies[1]. PF-0463481 is safe and well-tolerated and being developed for the treatment of diabetic nephropathy[2]. CCR2 CCR5
[1]. Gale JD, et al. A CCR2/5 Inhibitor, PF-04634817, Is Inferior to Monthly Ranibizumab in the Treatment of Diabetic Macular Edema. Invest Ophthalmol Vis Sci. 2018 May 1;59(6):2659-2669. [2]. Gale JD, et al. Effect of PF-04634817, an Oral CCR2/5 Chemokine Receptor Antagonist, on Albuminuria in Adults with Overt Diabetic Nephropathy. Kidney Int Rep. 2018 Aug 3;3(6):1316-1327.
Average Rating: 5
(Based on Reviews and 29 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *